NO323775B1 - Purininhibitorer av cyklinavhengig kinase 2 og IkB-alfa - Google Patents

Purininhibitorer av cyklinavhengig kinase 2 og IkB-alfa Download PDF

Info

Publication number: NO323775B1
Authority: NO; Norway
Prior art keywords: alkyl; halogen; hydroxy; lower alkyl; substituted
Prior art date: 1996-08-02

Application number

NO19990466A

Other languages

English (en)

Norwegian (no)

Other versions

NO990466L (no

NO990466D0 (no

Inventor

Robert T Lum

Cheri Lynn Blum

Richard Mackman

Steven R Schow

Michael M Wick

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-02

Filing date

1999-02-01

Publication date

2007-07-02

1999-02-01 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

1999-02-01 Publication of NO990466D0 publication Critical patent/NO990466D0/no

1999-03-25 Publication of NO990466L publication Critical patent/NO990466L/no

2007-07-02 Publication of NO323775B1 publication Critical patent/NO323775B1/no

Links

102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title description 11
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title description 11
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title description 10
239000003112 inhibitor Substances 0.000 title description 10
102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 title 1
101710083073 NF-kappa-B inhibitor alpha Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract description 127
229910052736 halogen Inorganic materials 0.000 claims abstract description 65
150000002367 halogens Chemical group 0.000 claims abstract description 65
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 64
-1 2,6,9-trisubstituted purine Chemical class 0.000 claims abstract description 59
125000003118 aryl group Chemical group 0.000 claims abstract description 51
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 48
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 41
239000001257 hydrogen Substances 0.000 claims abstract description 41
125000003545 alkoxy group Chemical group 0.000 claims abstract description 29
125000004414 alkyl thio group Chemical group 0.000 claims abstract description 28
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 23
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 20
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 84
125000004093 cyano group Chemical group *C#N 0.000 claims description 34
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
125000004104 aryloxy group Chemical group 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
125000004430 oxygen atom Chemical group O* 0.000 claims description 18
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 16
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 16
230000004663 cell proliferation Effects 0.000 claims description 12
125000004663 dialkyl amino group Chemical group 0.000 claims description 11
125000001544 thienyl group Chemical group 0.000 claims description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
150000001356 alkyl thiols Chemical class 0.000 claims description 7
125000004076 pyridyl group Chemical group 0.000 claims description 7
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
125000003342 alkenyl group Chemical group 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
239000000460 chlorine Substances 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
206010017533 Fungal infection Diseases 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 4
208000031888 Mycoses Diseases 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
229960005235 piperonyl butoxide Drugs 0.000 claims description 4
125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
201000005569 Gout Diseases 0.000 claims description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims description 3
229940121375 antifungal agent Drugs 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
206010025135 lupus erythematosus Diseases 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
208000030761 polycystic kidney disease Diseases 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 10
125000002346 iodo group Chemical group I* 0.000 claims 4
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 2
125000006189 4-phenyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 2
125000006187 phenyl benzyl group Chemical group 0.000 claims 2
RIVVLWUAIWLRCH-UHFFFAOYSA-N 2-(2-aminoethylamino)-2-[(2-aminopropylamino)-[2-(methylamino)ethylamino]amino]-3-methylbutan-1-ol Chemical compound NCCNC(C(C)C)(CO)N(NCCNC)NCC(C)N RIVVLWUAIWLRCH-UHFFFAOYSA-N 0.000 claims 1
ICZUIPAEZNDIQW-UHFFFAOYSA-N 2-[(2-aminoethylamino)-(2-aminopropylamino)amino]-3-methylbutan-1-ol Chemical compound NCCNN(C(C(C)C)CO)NCC(C)N ICZUIPAEZNDIQW-UHFFFAOYSA-N 0.000 claims 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 claims 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 claims 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
230000037396 body weight Effects 0.000 claims 1
208000035269 cancer or benign tumor Diseases 0.000 claims 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 1
125000000623 heterocyclic group Chemical group 0.000 abstract description 26
125000003107 substituted aryl group Chemical group 0.000 abstract description 13
125000000753 cycloalkyl group Chemical group 0.000 abstract description 10
125000004432 carbon atom Chemical group C* 0.000 abstract description 5
125000004404 heteroalkyl group Chemical group 0.000 abstract description 5
125000005346 substituted cycloalkyl group Chemical group 0.000 abstract description 5
125000005741 alkyl alkenyl group Chemical group 0.000 abstract description 4
125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract description 4
125000004475 heteroaralkyl group Chemical group 0.000 abstract description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 3
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
125000004897 3-methylbutylamino group Chemical group CC(CCN*)C 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
125000001174 sulfone group Chemical group 0.000 abstract 1
239000000243 solution Substances 0.000 description 34
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
235000002639 sodium chloride Nutrition 0.000 description 22
210000004027 cell Anatomy 0.000 description 20
238000000034 method Methods 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
239000000047 product Substances 0.000 description 16
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
239000007787 solid Substances 0.000 description 15
239000011535 reaction buffer Substances 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
108091000080 Phosphotransferase Proteins 0.000 description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
235000019439 ethyl acetate Nutrition 0.000 description 11
239000000499 gel Substances 0.000 description 11
102000020233 phosphotransferase Human genes 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
150000003573 thiols Chemical group 0.000 description 11
125000003368 amide group Chemical group 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
GKEFDRUWUYSFGW-UHFFFAOYSA-N 2,6-dichloro-9-propan-2-ylpurine Chemical compound N1=C(Cl)N=C2N(C(C)C)C=NC2=C1Cl GKEFDRUWUYSFGW-UHFFFAOYSA-N 0.000 description 9
108010057466 NF-kappa B Proteins 0.000 description 9
102000003945 NF-kappa B Human genes 0.000 description 9
229920002684 Sepharose Polymers 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
239000011324 bead Substances 0.000 description 6
229940126214 compound 3 Drugs 0.000 description 6
238000011534 incubation Methods 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
125000003396 thiol group Chemical class [H]S* 0.000 description 6
RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
FPVUCBMBMUHRDX-XMMPIXPASA-N [4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl (2r)-4-hydroxy-3-(4-hydroxyphenyl)-2-methyl-5-oxofuran-2-carboxylate Chemical compound C1=C(O)C(CC=C(C)C)=CC(COC(=O)[C@@]2(C)C(=C(O)C(=O)O2)C=2C=CC(O)=CC=2)=C1 FPVUCBMBMUHRDX-XMMPIXPASA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
210000001715 carotid artery Anatomy 0.000 description 5
230000022131 cell cycle Effects 0.000 description 5
238000001035 drying Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000001308 synthesis method Methods 0.000 description 5
UHQWIUXGLBJTRI-UHFFFAOYSA-N 2-chloro-n-[(4-methoxyphenyl)methyl]-7h-purin-6-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(Cl)=NC2=C1NC=N2 UHQWIUXGLBJTRI-UHFFFAOYSA-N 0.000 description 4
PDMSQJKBAMAEQE-UHFFFAOYSA-N 2-chloro-n-[(4-methoxyphenyl)methyl]-9-propan-2-ylpurin-6-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(Cl)=NC2=C1N=CN2C(C)C PDMSQJKBAMAEQE-UHFFFAOYSA-N 0.000 description 4
PHEWBOXSENDZMT-UHFFFAOYSA-N 2-chloro-n-[(4-phenylphenyl)methyl]-7h-purin-6-amine Chemical compound C=12NC=NC2=NC(Cl)=NC=1NCC(C=C1)=CC=C1C1=CC=CC=C1 PHEWBOXSENDZMT-UHFFFAOYSA-N 0.000 description 4
DVBOWBHHDZWSOC-UHFFFAOYSA-N 6-chloro-9-methylpurin-2-amine Chemical compound N1=C(N)N=C2N(C)C=NC2=C1Cl DVBOWBHHDZWSOC-UHFFFAOYSA-N 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
210000001168 carotid artery common Anatomy 0.000 description 4
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
125000004446 heteroarylalkyl group Chemical group 0.000 description 3
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
FHHUXCCJQONFEA-UHFFFAOYSA-N n-(6-chloro-9-methylpurin-2-yl)-2-methoxyacetamide Chemical compound COCC(=O)NC1=NC(Cl)=C2N=CN(C)C2=N1 FHHUXCCJQONFEA-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003212 purines Chemical class 0.000 description 3
238000011160 research Methods 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
FLJORSLXGMBXBK-UHFFFAOYSA-N 4-thiophen-2-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CS1 FLJORSLXGMBXBK-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108091007914 CDKs Proteins 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
239000004593 Epoxy Substances 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000018199 S phase Effects 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
RMSPOVPGDBDYKH-UHFFFAOYSA-N (4-phenylphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1C1=CC=CC=C1 RMSPOVPGDBDYKH-UHFFFAOYSA-N 0.000 description 1
QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
YKNLMMDEWQZCLJ-UHFFFAOYSA-N 1-(4-thiophen-2-ylphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1C1=CC=CS1 YKNLMMDEWQZCLJ-UHFFFAOYSA-N 0.000 description 1
JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
FXEOHOHZFXTENK-UHFFFAOYSA-N 2-propan-2-yl-7h-purine Chemical compound N1C(C(C)C)=NC=C2N=CN=C21 FXEOHOHZFXTENK-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
VRAIHTAYLFXSJJ-UHFFFAOYSA-N alumane Chemical compound [AlH3].[AlH3] VRAIHTAYLFXSJJ-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
230000000454 anti-cipatory effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000002737 cell proliferation kit Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940057307 dihydrate calcium sulfate Drugs 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
238000013156 embolectomy Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000003348 filter assay Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
238000007429 general method Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000013074 in-gel kinase assay Methods 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004524 naphthpyridyl group Chemical group C1(=CC=NC2=C1C1=CC=CC=C1C=C2)* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000008692 neointimal formation Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000005477 standard model Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19990466A 1996-08-02 1999-02-01 Purininhibitorer av cyklinavhengig kinase 2 og IkB-alfa NO323775B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/692,012 US5866702A (en)	1996-08-02	1996-08-02	Purine inhibitors of cyclin dependent kinase 2
PCT/US1997/013386 WO1998005335A1 (fr)	1996-08-02	1997-08-01	INHIBITEURS PURIQUES DE LA KINASE 2 ET IλB-α DEPENDANT DE LA CYCLINE

Publications (3)

Publication Number	Publication Date
NO990466D0 NO990466D0 (no)	1999-02-01
NO990466L NO990466L (no)	1999-03-25
NO323775B1 true NO323775B1 (no)	2007-07-02

Family

ID=24778922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990466A NO323775B1 (no)	1996-08-02	1999-02-01	Purininhibitorer av cyklinavhengig kinase 2 og IkB-alfa

Country Status (25)

Country	Link
US (1)	US5866702A (fr)
EP (1)	EP1021186B1 (fr)
JP (1)	JP2000515550A (fr)
KR (1)	KR100403336B1 (fr)
CN (1)	CN1161356C (fr)
AT (1)	ATE298572T1 (fr)
AU (1)	AU731778B2 (fr)
BR (1)	BR9710801A (fr)
CA (1)	CA2262454C (fr)
CZ (1)	CZ299381B6 (fr)
DE (1)	DE69733674T2 (fr)
DK (1)	DK1021186T3 (fr)
ES (1)	ES2242981T3 (fr)
GE (1)	GEP20022786B (fr)
HU (1)	HUP9902414A3 (fr)
IL (1)	IL128323A (fr)
NO (1)	NO323775B1 (fr)
NZ (1)	NZ334061A (fr)
PL (1)	PL189775B1 (fr)
PT (1)	PT1021186E (fr)
RU (1)	RU2220968C2 (fr)
SI (1)	SI1021186T1 (fr)
TR (1)	TR199900683T2 (fr)
UA (1)	UA71890C2 (fr)
WO (1)	WO1998005335A1 (fr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0874846B1 (fr) *	1995-11-01	2003-04-02	Novartis AG	Derives purines et procedes de preparation associes
FR2741881B1 (fr) *	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) *	1996-08-02	2004-09-14	Robert T. Lum	Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6153618A (en) *	1996-10-11	2000-11-28	Chiron Corporation	Inhibitors of glycogen synthase 3 kinase
DE19653646A1 (de) *	1996-12-20	1998-06-25	Hoechst Ag	Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
WO1999002162A1 (fr) *	1997-07-12	1999-01-21	Cancer Research Campaign Technology Limited	Derives de purine inhibant la kinase dependant de la cycline
US6573044B1 (en) *	1997-08-07	2003-06-03	The Regents Of The University Of California	Methods of using chemical libraries to search for new kinase inhibitors
JP2001516694A (ja)	1997-08-07	2001-10-02	ザリージェンツオブザユニバーシティオブカリフォルニア	プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
EP1418244A1 (fr) *	1997-12-19	2004-05-12	Affymetrix, Inc.	Exploitation de la génomique pour identifier des médicaments nouveaux
AU1926899A (en)	1997-12-19	1999-07-12	Affymetrix, Inc.	Exploiting genomics in the search for new drugs
US6642231B2 (en) *	1998-02-26	2003-11-04	Aventis Pharmaceuticals Inc.	6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en)	1998-02-26	2002-07-02	Aventis Pharmaceuticals Inc.	6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en)	1998-02-26	2002-11-12	Aventis Pharmaceuticals Inc.	6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
CA2231005A1 (fr)	1998-03-04	1999-09-04	Libor Havlicek	Inhibiteur de kynase dependant de la cycline
US6703395B2 (en)	1998-03-04	2004-03-09	Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic	Cyclin dependent kinase inhibitor
GB9806739D0 (en) *	1998-03-28	1998-05-27	Univ Newcastle Ventures Ltd	Cyclin dependent kinase inhibitors
AU778735B2 (en) *	1998-06-16	2004-12-16	Centre National De La Recherche Scientifique	Fused azepinone cyclin dependent kinase inhibitors
US6531477B1 (en) *	1998-10-13	2003-03-11	Dupont Pharmaceuticals Company	6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en)	1998-10-13	2003-05-06	Dupont Pharmaceuticals Company	6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
KR100377138B1 (ko) *	1998-11-10	2003-06-12	주식회사 엘지생명과학	퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU2004200192B2 (en) *	1999-02-01	2006-11-16	Gilead Palo Alto, Inc.	Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
ES2246829T3 (es) *	1999-02-01	2006-03-01	Cv Therapeutics Inc	Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.
KR100368515B1 (ko) *	1999-02-03	2003-01-24	주식회사 엘지생명과학	싸이클린 의존 키나아제 저해제 및 그의 제조 방법
KR20000055080A (ko) *	1999-02-03	2000-09-05	성재갑	싸이클린 의존 키나아제 저해제 및 그의 제조 방법
GB9903762D0 (en)	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
GB9904933D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds
US6624171B1 (en)	1999-03-04	2003-09-23	Smithkline Beecham Corporation	Substituted aza-oxindole derivatives
US6627633B2 (en) *	1999-03-17	2003-09-30	Albany Molecular Research, Inc.	6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) *	1999-03-17	2005-11-29	Amr Technology, Inc.	Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) *	1999-05-21	2001-07-27	Hoechst Marion Roussel Inc	Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
NZ516348A (en) *	1999-06-23	2003-06-30	Aventis Pharma Gmbh	Substituted benzimidazole
GB9918035D0 (en)	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
US6420384B2 (en) *	1999-12-17	2002-07-16	Ariad Pharmaceuticals, Inc.	Proton pump inhibitors
CA2396276A1 (fr) *	2000-01-07	2001-07-12	Universitaire Instelling Antwerpen	Derives de purine, procede de preparation et utilisation de ces derniers
KR20010077073A (ko) *	2000-01-31	2001-08-17	박호군	Ｃ-２,６,９ 위치에 치환된 이소프로필퓨린 유도체 및그의 제조 방법
GB0016877D0 (en) *	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
US6861524B2 (en)	2000-10-31	2005-03-01	Aventis Pharmaceuticals Inc.	Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
CA2432417A1 (fr) *	2000-12-20	2002-06-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.)	Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2818278B1 (fr) *	2000-12-20	2003-02-28	Sod Conseils Rech Applic	Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2818642B1 (fr) *	2000-12-26	2005-07-15	Hoechst Marion Roussel Inc	Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7605175B2 (en)	2001-03-02	2009-10-20	Gpc Biotech Ag	Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6667311B2 (en)	2001-09-11	2003-12-23	Albany Molecular Research, Inc.	Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en)	2001-09-11	2004-11-02	Amr Technology, Inc.	Heterocycle substituted purine derivatives as potent antiproliferative agents
CA2463563A1 (fr) *	2001-10-12	2003-04-17	Irm Llc	Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
ES2279903T3 (es) *	2001-12-18	2007-09-01	Cv Therapeutics, Inc.	Antagonistas del receptor a2a de adenosina.
DE60333955D1 (de) *	2002-02-15	2010-10-07	Gilead Palo Alto Inc	Polymerbeschichtung für medizinische Geräte
ES2347544T3 (es)	2002-03-13	2010-11-02	Janssen Pharmaceutica Nv	Inhibidores de histona-desacetilasas.
KR20040094672A (ko)	2002-03-13	2004-11-10	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
GB0219054D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New purine derivatives
GB0219052D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New puring derivatives
GB0219746D0 (en) *	2002-08-23	2002-10-02	Inst Of Ex Botany Ascr	Azapurine derivatives
US7273864B2 (en) *	2002-10-15	2007-09-25	The Scripps Research Institute	Compositions and methods for inducing osteogenesis
AU2004230867B2 (en)	2003-04-07	2010-09-09	Agennix Usa Inc.	Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
KR100573861B1 (ko) *	2003-07-18	2006-04-25	경동제약 주식회사	2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
CN100447143C (zh) *	2003-08-15	2008-12-31	Irm责任有限公司	作为rtk抑制剂的6-取代的苯胺基嘌呤
MXPA06001758A (es) *	2003-08-15	2006-08-11	Irm Llc	Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
KR20060121878A (ko) *	2003-09-25	2006-11-29	얀센 파마슈티카 엔.브이.	Ｈｉｖ를 저해하는 퓨린 유도체
WO2005063765A1 (fr)	2003-12-23	2005-07-14	Gpc Biotech, Inc.	Inhibiteurs des kinases dependantes des cyclines, compositions et utilisations connexes
JP2006056879A (ja) *	2004-07-21	2006-03-02	Kobe Univ	インスリン抵抗性の改善剤、及びそのスクリーニング方法
AU2005266312C1 (en)	2004-07-28	2011-06-16	Janssen Pharmaceutica N.V.	Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
AU2005276231A1 (en) *	2004-08-27	2006-03-02	Cyclacel Limited	Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases
GB0419175D0 (en) *	2004-08-27	2004-09-29	Cyclacel Ltd	Method of treatment and compositions
JP2008515939A (ja)	2004-10-13	2008-05-15	エフ．ホフマン−ラロシュアーゲー	Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン
EP1837033A4 (fr) *	2004-11-12	2010-05-26	Kazuhito Tomizawa	MÉDICAMENT CONTRE LE DIABÈTE CONTENANT UN INHIBITEUR DE Cdk5
KR100677396B1 (ko) *	2004-11-20	2007-02-02	엘지전자 주식회사	음성인식장치의 음성구간 검출방법
AU2006215386B2 (en) *	2005-02-16	2009-06-11	Astrazeneca Ab	Chemical compounds
AU2006261527B2 (en) *	2005-05-16	2012-11-22	Prometic Pharma Smt Limited	Purine derivatives and their use for treatment of autoimmune diseases
JP5321061B2 (ja)	2005-08-11	2013-10-23	アリアド・ファーマシューティカルズ・インコーポレイテッド	不飽和複素環誘導体
CN101360494A (zh) *	2005-11-22	2009-02-04	斯克里普斯研究学院	高效埃博霉素的化学合成
DK1979326T3 (da)	2006-01-19	2013-01-07	Janssen Pharmaceutica Nv	Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
ES2426448T3 (es)	2006-01-27	2013-10-23	Shanghai Hengrui Pharmaceutical Co. Ltd.	Inhibidores de proteína quinasa de pirrolo[3,2-c]piridin-4-ona 2-indolinona
GB0606283D0 (en) *	2006-03-29	2006-05-10	Cyclacel Ltd	Process
EP2125750B1 (fr) *	2007-02-26	2014-05-21	Vitae Pharmaceuticals, Inc.	Inhibiteurs d'urée et de carbamate de 11beta-hydroxystéroïde déshydrogénase 1 cycliques
GB0706632D0 (en) *	2007-04-04	2007-05-16	Cyclacel Ltd	New purine derivatives
WO2008135232A1 (fr) *	2007-05-02	2008-11-13	Riccardo Cortese	Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008138184A1 (fr)	2007-05-14	2008-11-20	Shanghai Hengrui Pharmaceutical Co.Ltd.	Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008138232A1 (fr)	2007-05-14	2008-11-20	Shanghai Hengrui Pharmaceutical Co., Ltd.	Dérivés pyrrolo-azotés hétérocycliques, leur préparation et leur utilisation pharmaceutique
US8329897B2 (en) *	2007-07-26	2012-12-11	Vitae Pharmaceuticals, Inc.	Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
FR2920776B1 (fr) *	2007-09-12	2012-09-28	Centre Nat Rech Scient	Utilisation de derives de purine pour la fabrication d'un medicament
US20110230464A1 (en) *	2007-10-26	2011-09-22	Paul Goldsmith	Purine derivatives useful as p13 kinase inhibitors
AR069207A1 (es) *	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (fr)	2007-12-11	2009-06-18	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques d'uree de la 11.beta.-hydroxysteroide dehydrogenase 1
TW200934490A (en) *	2008-01-07	2009-08-16	Vitae Pharmaceuticals Inc	Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) *	2008-01-24	2014-05-14	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
WO2009102428A2 (fr) *	2008-02-11	2009-08-20	Vitae Pharmaceuticals, Inc.	INHIBITEURS 1,3-OXAZEPAN-2-ONE ET 1,3-DIAZEPAN-2-ONE DE LA 11β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE (TYPE1)
US8598160B2 (en) *	2008-02-15	2013-12-03	Vitae Pharmaceuticals, Inc.	Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) *	2008-03-18	2014-07-02	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
US8242111B2 (en) *	2008-05-01	2012-08-14	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723034A1 (fr)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1
PL2300461T3 (pl)	2008-05-01	2013-09-30	Vitae Pharmaceuticals Inc	Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
US8569292B2 (en)	2008-05-01	2013-10-29	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
KR20110042153A (ko) *	2008-05-30	2011-04-25	제넨테크, 인크.	퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
MX2011000079A (es)	2008-07-03	2011-03-02	Sirtris Pharmaceuticals Inc	Bencimidazoles y analogos relacionados como moduladores de sirtuin.
JP5379160B2 (ja)	2008-07-25	2013-12-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
TW201016691A (en)	2008-07-25	2010-05-01	Boehringer Ingelheim Int	Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8846664B2 (en)	2008-11-12	2014-09-30	Ariad Pharmaceuticals, Inc.	Pyrazinopyrazines and derivatives as kinase inhibitors
CZ302122B6 (cs) *	2009-01-28	2010-10-20	Univerzita Palackého v Olomouci	Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2393807B1 (fr)	2009-02-04	2013-08-14	Boehringer Ingelheim International GmbH	Inhibiteurs cycliques de la 11beta -hydroxystéroïde déshydrogénase 1
US8592415B2 (en)	2009-02-11	2013-11-26	Reaction Biology Corp.	Selective kinase inhibitors
WO2010103473A1 (fr) *	2009-03-10	2010-09-16	Chu De Brest	Procédé de traitement des maladies polykystiques et de la leucémie lymphocytaire chronique
EP2414362B1 (fr) *	2009-04-03	2014-06-11	Verastem, Inc.	Composés de purine substituée par pyrimidine en tant qu'inhibiteurs d'une ou plusieurs kinases
TW201039034A (en) *	2009-04-27	2010-11-01	Chunghwa Picture Tubes Ltd	Pixel structure and the method of forming the same
MA33216B1 (fr)	2009-04-30	2012-04-02	Boehringer Ingelheim Int	Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
GEP20156309B (en) *	2009-04-30	2015-07-10	Vitae Pharmaceuticals Inc	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja)	2009-06-11	2015-01-21	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
EP2448938B9 (fr)	2009-06-29	2015-06-10	Incyte Corporation	Pyrimidinones comme inhibiteurs de pi3k
JP5749263B2 (ja)	2009-07-01	2015-07-15	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US8759359B2 (en) *	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) *	2009-12-18	2011-09-16	Incyte Corp	Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
AU2010343102B2 (en)	2009-12-29	2016-03-24	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
WO2011106168A1 (fr) *	2010-02-24	2011-09-01	Dcam Pharma Inc	Composés de purine pour le traitement de maladies auto-immunes et démyélinisantes
AR081823A1 (es)	2010-04-14	2012-10-24	Incyte Corp	DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
EP3399026B1 (fr)	2010-06-14	2024-06-26	The Scripps Research Institute	Reprogrammation de cellules pour leur conférer un nouveau destin
EP2582698B1 (fr)	2010-06-16	2016-09-14	Vitae Pharmaceuticals, Inc.	Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
JP5813106B2 (ja)	2010-06-25	2015-11-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
US8293736B2 (en)	2010-07-14	2012-10-23	F. Hoffmann La Roche Ag	Purine compounds selective for PI3K P110 delta, and methods of use
US8969556B2 (en) *	2010-10-12	2015-03-03	Case Western Reserve University	Purine-based triazoles
WO2012059416A1 (fr)	2010-11-02	2012-05-10	Boehringer Ingelheim International Gmbh	Combinaisons pharmaceutiques destinées au traitement de troubles du métabolisme
MX2013006858A (es)	2010-12-16	2013-07-29	Hoffmann La Roche	Compuesto triciclicos inhibidores de la pi3k y metodos de uso.
EP2655374B1 (fr)	2010-12-20	2019-10-23	Incyte Holdings Corporation	N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PL3513793T3 (pl)	2011-09-02	2021-09-20	Incyte Holdings Corporation	Heterocykloaminy jako inhibitory pi3k
PE20141228A1 (es)	2011-09-22	2014-10-01	Pfizer	Derivados de pirrolopirimidina y purina
EP2822935B1 (fr)	2011-11-17	2019-05-15	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase c-jun-terminale (jnk)
WO2013113762A1 (fr)	2012-01-31	2013-08-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et kits pour prédire le risque d'avoir un mélanome cutané chez un sujet
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2664619B1 (fr) *	2012-05-16	2017-07-12	Manros Therapeutics	Dérivés de purine en tant qu'outils pour le screening de composés anti-Alzheimer
FR3011240A1 (fr)	2013-10-01	2015-04-03	Centre Nat Rech Scient	Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
EP3057956B1 (fr)	2013-10-18	2021-05-05	Dana-Farber Cancer Institute, Inc.	Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7)
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN104086551B (zh) *	2014-06-06	2016-09-21	人福医药集团股份公司	化合物及其制备方法和用途
WO2015191677A1 (fr)	2014-06-11	2015-12-17	Incyte Corporation	Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
RS63963B1 (sr)	2015-02-27	2023-03-31	Incyte Holdings Corp	Postupak pripreme pi3k inhibitora
AU2016243529B2 (en) *	2015-03-27	2021-03-25	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (fr)	2015-05-11	2016-11-17	Incyte Corporation	Formes cristallines d'un inhibiteur de pi3k
JP7028766B2 (ja)	2015-09-09	2022-03-02	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼの阻害剤
WO2017091681A1 (fr)	2015-11-24	2017-06-01	Aclaris Therapeutics, Inc.	Inhibiteurs de kinase sélectifs
EP3388432A1 (fr)	2017-04-10	2018-10-17	Commissariat à l'Energie Atomique et aux Energies Alternatives	Dérivés de purine pour une utilisation comme médicament et dans le traitement de troubles neurodégénératifs ou neuro-inflammatoires
AU2019277560B2 (en)	2018-06-01	2025-04-24	Incyte Corporation	Dosing regimen for the treatment of PI3K related disorders
AU2019295632B2 (en)	2018-06-25	2025-03-06	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
WO2023140640A1 (fr) *	2022-01-21	2023-07-27	한양대학교 산학협력단	Dérivé hétéroaryle et ses utilisations
CN117659016A (zh) *	2022-08-26	2024-03-08	嘉兴优博生物技术有限公司	细胞周期蛋白调节剂
IL321433A (en)	2022-12-16	2025-08-01	Astrazeneca Ab	Purines 2,6,9 trimethylated
CN116813621A (zh) *	2023-06-08	2023-09-29	江南大学	9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4028353A (en) *	1971-07-29	1977-06-07	Polaroid Corporation	Novel chemical compounds
US4028358A (en) *	1973-09-04	1977-06-07	Liotta Charles L	6-Fluoro-9-perfluorobutyl purine
US4405781A (en) *	1981-03-02	1983-09-20	Polaroid Corporation	Method for preparing salts of 6-chloropurine
FI94133C (fi) *	1985-04-19	1995-07-25	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi
US4916224A (en) *	1988-01-20	1990-04-10	Regents Of The University Of Minnesota	Dideoxycarbocyclic nucleosides
MY104575A (en) *	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
GB9204015D0 (en) *	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
FR2699176B1 (fr) *	1992-12-11	1995-03-03	Adir	Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
US5540934A (en) *	1994-06-22	1996-07-30	Touitou; Elka	Compositions for applying active substances to or through the skin
EP0874846B1 (fr) *	1995-11-01	2003-04-02	Novartis AG	Derives purines et procedes de preparation associes
EP0802914B1 (fr) *	1995-11-14	2001-06-06	PHARMACIA & UPJOHN S.p.A.	Derives d'aryl- purine et pyridopyrimidine et d'heteroaryl- purine et pyridopyrimidine
FR2741881B1 (fr) *	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques

1996
- 1996-08-02 US US08/692,012 patent/US5866702A/en not_active Expired - Fee Related
1997
- 1997-01-08 UA UA99031160A patent/UA71890C2/uk unknown
- 1997-08-01 ES ES97936297T patent/ES2242981T3/es not_active Expired - Lifetime
- 1997-08-01 NZ NZ334061A patent/NZ334061A/xx unknown
- 1997-08-01 PT PT97936297T patent/PT1021186E/pt unknown
- 1997-08-01 KR KR10-1999-7000900A patent/KR100403336B1/ko not_active Expired - Fee Related
- 1997-08-01 AU AU39000/97A patent/AU731778B2/en not_active Ceased
- 1997-08-01 EP EP97936297A patent/EP1021186B1/fr not_active Expired - Lifetime
- 1997-08-01 JP JP10508039A patent/JP2000515550A/ja not_active Ceased
- 1997-08-01 CA CA002262454A patent/CA2262454C/fr not_active Expired - Fee Related
- 1997-08-01 CN CNB971983860A patent/CN1161356C/zh not_active Expired - Fee Related
- 1997-08-01 RU RU99104161/04A patent/RU2220968C2/ru not_active IP Right Cessation
- 1997-08-01 DE DE69733674T patent/DE69733674T2/de not_active Expired - Lifetime
- 1997-08-01 DK DK97936297T patent/DK1021186T3/da active
- 1997-08-01 CZ CZ0033899A patent/CZ299381B6/cs not_active IP Right Cessation
- 1997-08-01 HU HU9902414A patent/HUP9902414A3/hu unknown
- 1997-08-01 PL PL97331408A patent/PL189775B1/pl not_active IP Right Cessation
- 1997-08-01 GE GEAP19974693A patent/GEP20022786B/en unknown
- 1997-08-01 AT AT97936297T patent/ATE298572T1/de not_active IP Right Cessation
- 1997-08-01 IL IL12832397A patent/IL128323A/en not_active IP Right Cessation
- 1997-08-01 WO PCT/US1997/013386 patent/WO1998005335A1/fr not_active Ceased
- 1997-08-01 BR BR9710801-4A patent/BR9710801A/pt active Search and Examination
- 1997-08-01 SI SI9730717T patent/SI1021186T1/sl unknown
- 1997-08-01 TR TR1999/00683T patent/TR199900683T2/xx unknown
1999
- 1999-02-01 NO NO19990466A patent/NO323775B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2262454A1 (fr)	1998-02-12
CN1161356C (zh)	2004-08-11
NO990466L (no)	1999-03-25
SI1021186T1 (sl)	2005-12-31
BR9710801A (pt)	2001-11-27
AU3900097A (en)	1998-02-25
HUP9902414A2 (hu)	2001-04-28
CA2262454C (fr)	2006-02-07
AU731778B2 (en)	2001-04-05
DE69733674D1 (de)	2005-08-04
WO1998005335A1 (fr)	1998-02-12
KR100403336B1 (ko)	2003-10-30
IL128323A0 (en)	2000-01-31
HK1020884A1 (en)	2000-05-26
CZ299381B6 (cs)	2008-07-09
DE69733674T2 (de)	2006-05-04
ES2242981T3 (es)	2005-11-16
CN1231611A (zh)	1999-10-13
KR20000029781A (ko)	2000-05-25
PL189775B1 (pl)	2005-09-30
PL331408A1 (en)	1999-07-19
EP1021186B1 (fr)	2005-06-29
NO990466D0 (no)	1999-02-01
UA71890C2 (en)	2005-01-17
EP1021186A4 (fr)	2000-07-26
CZ33899A3 (cs)	2000-03-15
HUP9902414A3 (en)	2002-04-29
DK1021186T3 (da)	2005-10-17
EP1021186A1 (fr)	2000-07-26
IL128323A (en)	2001-11-25
GEP20022786B (en)	2002-09-25
NZ334061A (en)	2000-08-25
TR199900683T2 (xx)	2002-01-21
US5866702A (en)	1999-02-02
RU2220968C2 (ru)	2004-01-10
PT1021186E (pt)	2005-11-30
ATE298572T1 (de)	2005-07-15
JP2000515550A (ja)	2000-11-21

Publication	Publication Date	Title
NO323775B1 (no)	2007-07-02	Purininhibitorer av cyklinavhengig kinase 2 og IkB-alfa
NO327776B1 (no)	2009-09-21	Utvalgte 2,6,9-trisubstituerte purinforbindelser, farmasoytisk preparat omfattende slike og anvendelse for fremstilling av antifugale midler og farmasoytiske preparater for inhibering av celleproliferasjon
US6794390B2 (en)	2004-09-21	Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
WO1998005335A9 (fr)	1998-05-28	INHIBITEURS PURIQUES DE LA KINASE 2 ET IλB-α DEPENDANT DE LA CYCLINE
US12171755B2 (en)	2024-12-24	PAPD5 inhibitors and methods of use thereof
US20070299079A1 (en)	2007-12-27	4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM
CA2782684A1 (fr)	2011-06-09	Pyrazolopyrimidines et heterocycles associes en tant qu'inhibiteurs de ck2
CA2628455A1 (fr)	2007-05-24	Imidazopyrazines inhibant la proteine kinase
TW200530251A (en)	2005-09-16	Compositions useful as inhibitors of protein kinases
JP2006511458A (ja)	2006-04-06	アザプリン誘導体
US6790958B2 (en)	2004-09-14	Purine inhibitors of cyclin dependent kinase 2 & IKBA
US20250213571A1 (en)	2025-07-03	Tyk2 inhibitors and uses thereof
US5064947A (en)	1991-11-12	Selective adenosine reseptor compounds
Chu et al.	1975	Synthesis and biological activity of some 8-substituted selenoguanosine cyclic 3', 5'-phosphates and related compounds
JP3014000B2 (ja)	2000-02-28	選択的なアデノシンレセプター化合物
MXPA99001176A (en)	2000-05-01	PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I&kgr;B-&agr;
AU2004200192B2 (en)	2006-11-16	Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa

Legal Events

Date	Code	Title	Description
2011-04-04	MM1K	Lapsed by not paying the annual fees